GuanosineCAS# 118-00-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 118-00-3 | SDF | Download SDF |
| PubChem ID | 765 | Appearance | Powder |
| Formula | C10H13N5O5 | M.Wt | 283.2 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble to 56 mg/mL (197.71 mM) in DMSO | ||
| Chemical Name | 2-amino-9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one | ||
| SMILES | C1=NC2=C(N1C3C(C(C(O3)CO)O)O)NC(=NC2=O)N | ||
| Standard InChIKey | NYHBQMYGNKIUIF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Guanosine and GMP show anticonvulsant properties, which may be related with antagonism of glutamate receptors; they also prevent seizures induced by quinolinic acid in mice.Guanosine protects against renal ischemic injury by replenishing GTP stores and preventing tubular apoptosis. |
| Targets | GABA Receptor |
| In vivo | Guanosine and GMP prevent seizures induced by quinolinic acid in mice.[Pubmed: 10793184]Brain Res. 2000 May 2;864(1):40-3.In the mammalian CNS, glutamate and GABA are the principal neurotransmitters mediating excitatory and inhibitory synaptic events, respectively, and have been implicated in the neurobiology of seizures. Guanine-based purines, including the nucleoside Guanosine and the nucleotide GMP, have been shown to antagonize glutamatergic activity at the receptor level and the other purine nucleoside adenosine is a well-known modulator of seizure threshold. |
| Animal Research | Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury.[Pubmed: 11696573 ]J Clin Invest. 2001 Nov;108(9):1291-8.Ischemic injury to the kidney is characterized in part by nucleotide depletion and tubular cell death in the form of necrosis or apoptosis. Recently, we linked anoxia-induced apoptosis in renal cell cultures specifically to the depletion of GTP. We therefore hypothesized that enhancing GTP repletion in vivo might protect function by reducing apoptosis in postischemic tubules. |
Guanosine Dilution Calculator
Guanosine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5311 mL | 17.6554 mL | 35.3107 mL | 70.6215 mL | 88.2768 mL |
| 5 mM | 0.7062 mL | 3.5311 mL | 7.0621 mL | 14.1243 mL | 17.6554 mL |
| 10 mM | 0.3531 mL | 1.7655 mL | 3.5311 mL | 7.0621 mL | 8.8277 mL |
| 50 mM | 0.0706 mL | 0.3531 mL | 0.7062 mL | 1.4124 mL | 1.7655 mL |
| 100 mM | 0.0353 mL | 0.1766 mL | 0.3531 mL | 0.7062 mL | 0.8828 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rabeprazole sodium
Catalog No.:BCC5227
CAS No.:117976-90-6
- Rabeprazole
Catalog No.:BCC5228
CAS No.:117976-89-3
- Luzindole
Catalog No.:BCC6826
CAS No.:117946-91-5
- GLYX 13
Catalog No.:BCC6013
CAS No.:117928-94-6
- Boc-N-Me-Nle-OH
Catalog No.:BCC2611
CAS No.:117903-25-0
- Forsythoside H
Catalog No.:BCN6431
CAS No.:1178974-85-0
- 7,4'-Dihydroxyhomoisoflavanone
Catalog No.:BCN3582
CAS No.:1178893-64-5
- Fmoc-Thr(Bzl)-OH
Catalog No.:BCC3550
CAS No.:117872-75-0
- L-CCG-lll
Catalog No.:BCC6608
CAS No.:117857-95-1
- L-CCG-l
Catalog No.:BCC6609
CAS No.:117857-93-9
- Loreclezole hydrochloride
Catalog No.:BCC7009
CAS No.:117857-45-1
- Ac-Asp(OtBu)-OH
Catalog No.:BCC2880
CAS No.:117833-18-8
- Hydrastine
Catalog No.:BCC8187
CAS No.:118-08-1
- Cinchonine
Catalog No.:BCN2464
CAS No.:118-10-5
- Syringin
Catalog No.:BCN6059
CAS No.:118-34-3
- Trimethylgallic acid
Catalog No.:BCN3424
CAS No.:118-41-2
- Maltol
Catalog No.:BCN4819
CAS No.:118-71-8
- Ortho-Hydroxyacetophenone
Catalog No.:BCN3827
CAS No.:118-93-4
- Acetylepipodophyllotoxin
Catalog No.:BCN6056
CAS No.:1180-35-4
- Limonin
Catalog No.:BCN6057
CAS No.:1180-71-8
- Blumeatin
Catalog No.:BCN6055
CAS No.:118024-26-3
- PHM 27 (human)
Catalog No.:BCC5869
CAS No.:118025-43-7
- Eriodictyol-6-glucoside
Catalog No.:BCN8026
CAS No.:118040-45-2
- 4-O-Methylgrifolic acid
Catalog No.:BCN7287
CAS No.:118040-60-1
Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury.[Pubmed:11696573]
J Clin Invest. 2001 Nov;108(9):1291-8.
Ischemic injury to the kidney is characterized in part by nucleotide depletion and tubular cell death in the form of necrosis or apoptosis. Recently, we linked anoxia-induced apoptosis in renal cell cultures specifically to the depletion of GTP. We therefore hypothesized that enhancing GTP repletion in vivo might protect function by reducing apoptosis in postischemic tubules. Male C57 black mice (the "I" group of animals) underwent bilateral renal artery clamp for 32 minutes to induce ischemia and then received either normal saline ("NS") or Guanosine ("G"). After 1 hour of reperfusion, renal GTP levels in NS/I were reduced to nearly half of those in sham operated mice, whereas these levels were nearly unchanged in G/I mice. Morphologic examination of tubular injury revealed no significant differences between the two groups. However, there was a significant reduction in the number of apoptotic tubular cells in the medulla in the G/I group as compared with the NS/I group. At 24 hours, creatinine was significantly elevated in the NS/I group, compared to the G/I group. We conclude that Guanosine protects against renal ischemic injury by replenishing GTP stores and preventing tubular apoptosis.
Guanosine and GMP prevent seizures induced by quinolinic acid in mice.[Pubmed:10793184]
Brain Res. 2000 May 2;864(1):40-3.
In the mammalian CNS, glutamate and GABA are the principal neurotransmitters mediating excitatory and inhibitory synaptic events, respectively, and have been implicated in the neurobiology of seizures. Guanine-based purines, including the nucleoside Guanosine and the nucleotide GMP, have been shown to antagonize glutamatergic activity at the receptor level and the other purine nucleoside adenosine is a well-known modulator of seizure threshold. In the present study we investigated the anticonvulsant effect of i. p. Guanosine and GMP against seizures induced by the glutamate agonist quinolinic acid (QA) or the GABA(A) antagonist picrotoxin in mice. Animals were pretreated with an i.p. injection of saline, Guanosine or GMP 30 min before either an i.c.v. injection of 4 microliter QA (36.8 nmol) or a subcutaneous injection of picrotoxin (3.2 mg/kg). All animals pretreated with vehicle followed by QA or picrotoxin presented seizures, which were completely prevented by the NMDA antagonist MK-801 and the GABA agonist phenobarbital, respectively. Guanosine and GMP dose-dependently protected against QA-induced seizures, up to 70 and 80% at 7.5 mg/kg, with ED(50)=2. 6+/-0.4 and 1.7+/-0.6 mg/kg, respectively. Conversely, neither Guanosine, GMP nor MK-801 affected picrotoxin-induced seizures, indicating some degree of specificity towards the glutamatergic system. This study suggests anticonvulsant properties of i.p. Guanosine and GMP, which may be related with antagonism of glutamate receptors.
